MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Active:	Yes
Cancer Type:	Unknown Primary	NCT ID:	NCT06097728
Trial Phases:	Phase III	Protocol IDs:	D7988C00001 (primary) NCI-2024-02750 2023-000067-32 2023-503231-17-00
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT06097728

Summary

This is a phase III, randomized, open-label, multicenter, global study to determine the
efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the
investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants
with unresectable pleural mesothelioma.

Objectives

Adult patients with histologically proven diagnosis of pleural mesothelioma with advanced
unresectable disease are eligible to be enrolled. Patients will be randomized 1:1 to
receive Volrustomig (MEDI5752) + Carboplatin + Pemetrexed or the investigator's choice of
platinum+Pemetrexed or Nivolumab+Ipilimumab, based on their histology.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.